Asymmetric synthesis of benzoxazinones via new intermediates

A compound, aniline technology, applied in the field of human immunodeficiency virus reverse transcriptase inhibitors, can solve problems such as expensive and unstable

Inactive Publication Date: 2000-04-26
DU PONT PHARMA CO +1
View PDF3 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] To this end, the present invention provides a novel benzylation method using acid-catalyzed benzyl alcohols instead of the corresponding benzyl chloride analogues, which are relatively more expensive and unstable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Asymmetric synthesis of benzoxazinones via new intermediates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0216] Preparation of N-(4-chlorophenyl)-2,2-dimethylpropanamide. 4-Chloroaniline (52.7kg, 413mol) was dissolved in a mixture of tert-butyl methyl ether (180kg), 30% aqueous sodium hydroxide solution (61.6kg, 463mol) and water (24.2kg), then cooled to 15°C. To the resulting slurry was added trimethylacetyl chloride (52.2 kg, 448 mol) over 1 hour keeping the temperature below 40°C. After stirring at 30°C for 30 minutes, the slurry was cooled to -10°C and held for 2 hours. The product was collected by filtration, washed with a 90 / 10 water / methanol solution (175 kg), and dried in vacuo to afford 85 kg (97% yield) of the title compound as a crystalline solid.

[0217] mp152-153°C; 1 H NMR (300MHz, CDCl 3 )δ7.48(d, J=9Hz, 2H)7.28(d, J=9Hz, 2H); 13 C NMR (75MHz, CDCl 3 )d176.7, 136.6, 129.1, 128.9, 121.4, 39.6, 27.6.

[0218] Preparation of N-(4-fluorophenyl)-2,2-dimethylpropanamide. Those skilled in the art of organic synthesis should know that this compound can be e...

Embodiment 2

[0220] Preparation of the hydrochloride hydrate of 4-chloro-2-trifluoroacetylaniline. N-(4-chlorophenyl)-2,2-dimethylpropanamide (36.7kg, 173mol) was added to TMEDA (20.2kg, 174mol) in anhydrous tert-butyl methyl ether (271.5kg) solution, and then Cool to -20°C. To this cold slurry was added 2.7N n-butyllithium in hexane (101.9 kg, 393 mol) while maintaining the temperature below 5°C. After aging at 0-5°C for 2 hours, the solution was cooled to below -15°C and reacted rapidly with ethyl trifluoroacetate (34.5 kg, 243 mol). After 30 minutes, the resulting solution was poured into 3N HCl (196 L, 589 mol) maintaining the temperature below 25 °C. After removing the aqueous phase, the organic solution was concentrated by distilling off approximately 200 L of solvent. Acetic acid (352 kg) was added while 325 kg of solvent was distilled off under 100 mm vacuum. After the solution was cooled to 30°C, 12N HCl (43.4kg, 434mol) was added, and the mixture was heated to 65-70°C for 4 h...

Embodiment 3-a

[0223] Preparation of 4-chloro-2-trifluoroacetylaniline. 4-Chloro-2-trifluoroacetylaniline hydrochloride hydrate (17.1 g, 62 mmol) was stirred in a mixture of toluene (100 ml) and water (50 ml). with saturated NaHCO 3 The solution neutralized the mixture to pH7. The organic phase was then concentrated in vacuo and the residue was recrystallized from heptane to afford 12.5 g (91%) of the title compound as yellow needles: mp 98-99°C.

[0224] 1 H NMR (300MHz, CDCl 3 )δ7.70(t, J=2Hz, 1H), 7.32(dd, J=2, 9Hz, 1H), 6.7(d, J=9Hz, 1H), 6.44(brs, 2H); 13 C NMR (75MHz CDCl 3 )δ180.0, 151.6, 136.9, 130.1, 120.9, 119.0, 116.8, 111.4; 19 F NMR (282 MHz, CDCl 3 )δ-70.3.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides novel methods for the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one of formula (VI-i) which is useful as a human immunodeficiency virus (HIV) reverse transcriptase inhibitor. In an embodiment, the present invention provides a process for the preparation of an amino alcohol compound of formula (V-i) comprising adding a toluene solution of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone to a toluene solution of a compound of formula (III-i), via a compound of formula (IV-i).

Description

field of invention [0001] The present invention provides the asymmetric synthesis of (S)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazine-2- A new approach to ketones, compounds that can be used as human immunodeficiency virus (HIV) reverse transcriptase inhibitors. Background of the invention [0002] Reverse transcription is a common feature of retroviral replication. Viral replication requires a virally encoded reverse transcriptase to generate a DNA replica with viral sequences by retroviral RNA genome. Since inhibition of virally encoded reverse transcriptase interrupts viral replication, reverse transcriptase is clinically a relevant target for chemotherapy of retroviral infections. [0003] Many compounds are effective in treating human immunodeficiency virus (HIV), a retrovirus that progressively destroys the human immune system, resulting in AIDS. Known therapeutics effective in the treatment by inhibiting HIV reverse tra...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P31/18A61P37/04C07C213/00C07D265/16C07C213/02C07C215/68C07C215/70C07C217/58C07C221/00C07C225/22C07D265/18
CPCC07C213/02C07C221/00C07C2101/02C07C213/00C07D265/18C07C2601/02A61P31/18A61P37/04C07C215/68C07C217/58C07C225/22
Inventor M·E·皮尔斯C·Y·陈A·乔杜里L·A·拉德斯卡L·谭D·赵
Owner DU PONT PHARMA CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap